FibroBiologics Inc. (NASDAQ:FBLG) Short Interest Update

FibroBiologics Inc. (NASDAQ:FBLG) was the recipient of a large decline in short interest in February. As of February 13th, there was short interest totaling 630,020 shares, a decline of 26.0% from the January 29th total of 851,743 shares. Approximately 1.1% of the company’s stock are short sold. Based on an average trading volume of 1,232,115 shares, the short-interest ratio is currently 0.5 days. Based on an average trading volume of 1,232,115 shares, the short-interest ratio is currently 0.5 days. Approximately 1.1% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on FBLG. D. Boral Capital decreased their price target on FibroBiologics from $15.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, February 25th. HC Wainwright dropped their target price on shares of FibroBiologics to $4.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of FibroBiologics in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $5.50.

Insider Transactions at FibroBiologics

In related news, General Counsel Ruben A. Garcia purchased 140,000 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The stock was acquired at an average price of $0.34 per share, for a total transaction of $47,600.00. Following the completion of the purchase, the general counsel owned 140,000 shares in the company, valued at approximately $47,600. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 13.00% of the stock is owned by company insiders.

Institutional Trading of FibroBiologics

Large investors have recently modified their holdings of the stock. AQR Capital Management LLC bought a new position in shares of FibroBiologics in the first quarter worth about $29,000. XTX Topco Ltd raised its position in FibroBiologics by 160.0% during the 2nd quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock worth $29,000 after purchasing an additional 28,276 shares during the last quarter. Ethos Financial Group LLC lifted its stake in shares of FibroBiologics by 100.0% in the second quarter. Ethos Financial Group LLC now owns 48,848 shares of the company’s stock worth $30,000 after acquiring an additional 24,424 shares during the period. AMG National Trust Bank bought a new stake in shares of FibroBiologics in the 4th quarter valued at $31,000. Finally, Jane Street Group LLC acquired a new position in FibroBiologics in the fourth quarter valued at approximately $34,000.

FibroBiologics Stock Performance

FBLG traded up $0.09 during mid-day trading on Monday, reaching $0.42. The stock had a trading volume of 2,540,284 shares, compared to its average volume of 1,339,846. The firm’s fifty day simple moving average is $0.29 and its two-hundred day simple moving average is $0.39. The stock has a market capitalization of $28.19 million, a P/E ratio of -0.96 and a beta of -0.69. FibroBiologics has a 52 week low of $0.22 and a 52 week high of $1.53.

FibroBiologics (NASDAQ:FBLG) last released its quarterly earnings data on Tuesday, February 24th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.06. As a group, analysts expect that FibroBiologics will post -0.53 EPS for the current fiscal year.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.